Trametinib and Interstitial Lung Disease

In this article, we will discuss Trametinib and Interstitial Lung Disease. So, let’s get started.

Trametinib and Interstitial Lung Disease

In clinical trials of single-agent Trametinib, ILD or pneumonitis occurred in 2% of patients. In the METRIC study, 2.4% of patients treated with Trametinib developed ILD or pneumonitis; all five patients required hospitalization. In the COMBI-d, COMBI-AD, and BRF113928 studies, 1.0%, < 1%, and 2.2% of patients receiving Trametinib and dabrafenib developed pneumonitis, respectively.

Withhold Trametinib in patients presenting with new or progressive pulmonary symptoms and findings including cough, dyspnea, hypoxia, pleural effusion, or infiltrates, pending clinical investigations. Permanently discontinue Trametinib for patients diagnosed with treatment-related ILD or pneumonitis.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.